EORTC - European Organisation for Research and Treatment of Cancer

📅 Get ready to make the most of 2025 with EORTC’s upcoming events!   6th EORTC QoL in Cancer Clinical Trials Conference 12-13 May 2025 Barcelona, Spain 👉 https://lnkd.in/dFbKV-Ju   Clinical Trial Statistics for Non-Statisticians Workshop 10-13 June 2025 Brussels, Belgium 👉 https://lnkd.in/da8JKPzQ   25th MCCR Workshop 14-20 June 2025 Sint Michielsgestel, Netherlands 👉 https://lnkd.in/dmsfgGFu   Patient Days End of 2025 Brussels, Belgium   EBCC 15 25-27 March 2026 Barcelona, Spain   38th ENA Symposium 18-20 November 2025 Barcelona, Spain   #CancerResearch #ClinicalTrials #Oncology #EORTCevents

Have you heard about the new findings from the MINDACT (EORTC 10041/BIG3-04) phase III trial? The findings reveal that the MammaPrint 70-gene signature can help guide chemotherapy decisions for invasive lobular carcinoma (ILC) patients. Key findings: 🔬16% of ILC cases are 70-gene high-risk with poor outcomes. 🔬Survival rates by 70-gene risk are similar for ILC and NST patients. 🔬No chemotherapy for high clinical, low genomic risk ILC patients should be considered. 🔬MammaPrint could facilitate chemotherapy decisions for patients diagnosed with ILC. Discover how MammaPrint could transform treatment decisions for ILC patients. 👇 🔗Read more: https://lnkd.in/edxSA_wm   #BreastCancerResearch #ILC #MammaPrint #MINDACT #CancerResearch #Oncology #ClinicalTrials #EORTCBreast BIG against breast cancer

📢 New trial alert! We're launching the EORTC-2334-BTG LUMEN-1 clinical trial to explore [177Lu] Lu-DOTATATE as a new treatment for recurrent meningioma. This trial will investigate the effectiveness of this new treatment in targeting a specific receptor found in most meningiomas. It involves 136 patients across 35 sites in 10 European countries, aiming to improve progression-free survival and quality of life. 🔗 Learn more about the LUMEN-1 trial: https://lnkd.in/eQPgGR8p. #ClinicalTrial #Meningioma #CancerResearch #LUMEN1

🧠 This Brain Awareness Week, we celebrate the incredible work of the EORTC Brain Tumour Group (BTG) in advancing neuro-oncology research and improving patient care. The BTG focuses on initiating and conducting research to challenge, redefine, and develop standards of care in neuro-oncology, primarily targeting diffuse gliomas, meningiomas, and rare brain tumours. Scroll the carousel to find out about our current BTG activities 👉 For more information:  https://lnkd.in/epd3d_Nd #BrainAwarenessWeek #EORTCbrain #CancerResearch #LEGATO #LUMEN1 #CancerResearch

New advancements in breast cancer research! 🧬 Our latest publication explores the use of machine learning to characterise the tumour-immune microenvironment in the EORTC 10994/BIG 1-00 trial. Discover how AI is helping us understand immune infiltrates and their prognostic implications. 👉 Read more: https://lnkd.in/exzn6GYF #BreastCancerResearch #MachineLearning #EORTCbreast

📢 Join our team in Brussels as a Clinical Research Associate (CRA) and play a pivotal role in ensuring the success of clinical trials! As a CRA, you'll oversee on-site monitoring to uphold protocol adherence and regulatory compliance, fostering collaboration between investigators and site scientists. Are you proactive, dynamic, and have a background in Health Sciences with prior Oncology experience? Are you fluent in English and open to travel? ✈️ Apply now: https://lnkd.in/e6iscNVi #CancerResearch #WorkWithUs #Vacancy #Jobs #ClinicalResearchAssociate #HealthSciences #Oncology

Don't miss the next PAMM-EORTC meeting in La Laguna Spain next month! Happy to introduce our keynote speakers: Richard Clarkson, Serena Pellegatta, Stefano Alcaro, Nelson Dusetti and Joseph Ciccolini This 2025 edition will focus on tackling #cancer #resistance. Be there or be squared! Registration details on https://lnkd.in/eFFXjYJ8 #oncology #translational #research #drugs EORTC - European Organisation for Research and Treatment of Cancer

🎉Live from London: we are proud to join Walgreens Boots Alliance (WBA) in celebrating a decade of impact through their ESG Report. As part of this milestone event, EORTC CEO Denis Lacombe participates in the panel discussion, Enabling Healthy Futures: Together in Partnership, to highlight how collaboration drives progress in clinical cancer research and patient care. For over 12 years, our partnership with WBA has helped us develop innovative clinical research infrastructures, like #SPECTAplatform and #E2RADIatE, bringing better access to evidence-based cancer treatments for patients across Europe. Looking ahead, we remain committed to driving progress in cancer treatment and care, ensuring no patient is left behind. Thank you, WBA, for your continued support in shaping a healthier future, together! Una Kent David Macdonald #ClinicalCancerResearch #WBA  #Oncology #LeavingNoCancerPatientBehind

🌍 Exciting news! Last week, our CEO, Denis Lacombe, was in Rome to discuss clinical trial access. Tackling inequities in clinical trials access is crucial, as geographical disparities, socio-economic status, and rare diseases have been identified as limiting factors. While some trials need restricted access for safety, pragmatic trials can be inclusive of all patients in the real world and promote therapeutic progress applicable to all. World Health Organization #HealthcareEquity #ClinicalTrials #CancerResearch #Oncology

👏 Congratulations to Guillaume Grisay and the EORTC network for their great contribution to the latest publication by the European Journal of Cancer.   Find out more: https://lnkd.in/ex6j4kxe